GLP-1 receptor agonists including semaglutide have been shown to offer benefits for glycemic control, weight loss and cardiovascular protection in type 2 diabetes. But where a patient requires more glycemic control, would a higher dose be of help?

The SUSTAIN FORTE trial was a randomized, double-blind, phase 3B trial that aimed to establish whether a higher dose of semaglutide was superior to the highest approved maintenance dose for glycemic control. Join Dr Juan Pablo Frias for a summary of the trial data and its potential implications for clinical practice.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

Reference:

Frías JP, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563-574.

Disclosures:

Dr Juan Pablo Frías declares the following:

Grants/Research Support, Advisory Boards, Honoraria receipt - Novo Nordisk, Eli Lilly, Sanofi, Pfizer

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding Information

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.